Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12188/7938
Title: Correlation of Immunohistochemistry and Fluorescence in Situ Hybridization for HER-2 Assessment in Breast Cancer Patients: Single Centre Experience
Authors: Bogdanovska-Todorovska, Magdalena 
Kostadinova-Kunovska, Slavica 
Jovanovik, Rubens 
Krsteska, Blagica 
Kondov, Goran 
Kondov, Borislav 
Petrushevska, Gordana 
Keywords: Breast cancer; HER – 2; Fluorescence in situ hybridisation; Immunohistochemistry
Issue Date: 15-Apr-2018
Publisher: ID Design 2012/DOOEL Skopje
Journal: Open access Macedonian journal of medical sciences
Abstract: BACKGROUND: Accurate assessment of HER-2 is imperative in selecting patients for targeted therapy. Most commonly used test methods for HER-2 are immunohistochemistry (IHC) and fluorescence in situ hybridisation (FISH). We evaluated the concordance between FISH and IHC for HER-2 in breast cancer samples using Food and Drug Administration approved tests. MATERIAL AND METHODS: Archived paraffin tissue blocks from 73 breast cancer patients were used. HER-2 immunostaining was performed using Ventana anti–HER-2 monoclonal antibody. The FISH assay was performed using PathVysion™ HER-2 DNA Probe Kit. RESULTS: Of the 73 cases 68.5% were IHC 0/1+, 15.07% were IHC 2+ and 16.44% were IHC 3+. Successful hybridisation was achieved in 72 cases. HER-2 FISH amplification was determined in 16.67% cases. Ten IHC 3+ and two IHC 2+ cases were FISH positive. Two of the IHC 3+ cases were FISH negative. Concordance rate was 100%, 18.18% and 83.33% for IHC 0/1+, 2+ and 3+ group, respectively. Total concordance was 84.72%, kappa 0.598 (p < 0.0001). The sensitivity of IHC in detecting IHC 2+ and IHC 3+ cases was 16.7% and 83.3%, and the specificity was 85% and 96.67%, respectively. CONCLUSION: The consistency between the methods was highest for IHC negative and lowest for IHC equivocal cases. The immunohistochemistry showed high sensitivity for IHC 2+/3+ cases and high specificity for IHC 3+ cases. Our results support the view that false-positive rather than false-negative IHC results are a problem with HER-2/IHC testing, and that IHC should be used as an initial screening test, but IHC 2+/ 3+ results should be confirmed by FISH.
URI: http://hdl.handle.net/20.500.12188/7938
ISSN: 1857-9655
DOI: 10.3889/oamjms.2018.124
Appears in Collections:Faculty of Medicine: Journal Articles

Show full item record

Page view(s)

14
checked on Oct 20, 2020

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.